Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Copyright © 2021 Massachusetts Medical Society..
BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease.
METHODS: We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response.
RESULTS: A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P = 0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy.
CONCLUSIONS: Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.).
| Errataetall: |
CommentIn: Nat Rev Rheumatol. 2021 Sep;17(9):510. - PMID 34345020 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 385(2021), 1 vom: 01. Juli, Seite 46-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kastritis, Efstathios [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.07.2021 Date Revised 13.09.2021 published: Print ClinicalTrials.gov: NCT03201965 CommentIn: Nat Rev Rheumatol. 2021 Sep;17(9):510. - PMID 34345020 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2028631 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327392614 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327392614 | ||
| 003 | DE-627 | ||
| 005 | 20231225200703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2028631 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327392614 | ||
| 035 | |a (NLM)34192431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kastritis, Efstathios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.07.2021 | ||
| 500 | |a Date Revised 13.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03201965 | ||
| 500 | |a CommentIn: Nat Rev Rheumatol. 2021 Sep;17(9):510. - PMID 34345020 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells. Daratumumab, a human CD38-targeting antibody, may improve outcomes for this disease | ||
| 520 | |a METHODS: We randomly assigned patients with newly diagnosed AL amyloidosis to receive six cycles of bortezomib, cyclophosphamide, and dexamethasone either alone (control group) or with subcutaneous daratumumab followed by single-agent daratumumab every 4 weeks for up to 24 cycles (daratumumab group). The primary end point was a hematologic complete response | ||
| 520 | |a RESULTS: A total of 388 patients underwent randomization. The median follow-up was 11.4 months. The percentage of patients who had a hematologic complete response was significantly higher in the daratumumab group than in the control group (53.3% vs. 18.1%) (relative risk ratio, 2.9; 95% confidence interval [CI], 2.1 to 4.1; P<0.001). Survival free from major organ deterioration or hematologic progression favored the daratumumab group (hazard ratio for major organ deterioration, hematologic progression, or death, 0.58; 95% CI, 0.36 to 0.93; P = 0.02). At 6 months, more cardiac and renal responses occurred in the daratumumab group than in the control group (41.5% vs. 22.2% and 53.0% vs. 23.9%, respectively). The four most common grade 3 or 4 adverse events were lymphopenia (13.0% in the daratumumab group and 10.1% in the control group), pneumonia (7.8% and 4.3%, respectively), cardiac failure (6.2% and 4.8%), and diarrhea (5.7% and 3.7%). Systemic administration-related reactions to daratumumab occurred in 7.3% of the patients. A total of 56 patients died (27 in the daratumumab group and 29 in the control group), most due to amyloidosis-related cardiomyopathy | ||
| 520 | |a CONCLUSIONS: Among patients with newly diagnosed AL amyloidosis, the addition of daratumumab to bortezomib, cyclophosphamide, and dexamethasone was associated with higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression. (Funded by Janssen Research and Development; ANDROMEDA ClinicalTrials.gov number, NCT03201965.) | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Palladini, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Minnema, Monique C |e verfasserin |4 aut | |
| 700 | 1 | |a Wechalekar, Ashutosh D |e verfasserin |4 aut | |
| 700 | 1 | |a Jaccard, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hans C |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchorawala, Vaishali |e verfasserin |4 aut | |
| 700 | 1 | |a Gibbs, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Mollee, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Venner, Christopher P |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Schönland, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Gatt, Moshe E |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Kenshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kihyun |e verfasserin |4 aut | |
| 700 | 1 | |a Cibeira, M Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Beksac, Meral |e verfasserin |4 aut | |
| 700 | 1 | |a Libby, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Valent, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Hungria, Vania |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Sandy W |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenzweig, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bumma, Naresh |e verfasserin |4 aut | |
| 700 | 1 | |a Huart, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Dimopoulos, Meletios A |e verfasserin |4 aut | |
| 700 | 1 | |a Bhutani, Divaya |e verfasserin |4 aut | |
| 700 | 1 | |a Waxman, Adam J |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Stacey A |e verfasserin |4 aut | |
| 700 | 1 | |a Zonder, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Selay |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Timon |e verfasserin |4 aut | |
| 700 | 1 | |a Manier, Salomon |e verfasserin |4 aut | |
| 700 | 1 | |a Roeloffzen, Wilfried |e verfasserin |4 aut | |
| 700 | 1 | |a Jamroziak, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Kwok, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Shimazaki, Chihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jin-Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Crusoe, Edvan |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Tahamtan |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, NamPhuong |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Vasey, Sandra Y |e verfasserin |4 aut | |
| 700 | 1 | |a Tromp, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Schecter, Jordan M |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Brendan M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Sen H |e verfasserin |4 aut | |
| 700 | 1 | |a Vermeulen, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Merlini, Giampaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Comenzo, Raymond L |e verfasserin |4 aut | |
| 700 | 0 | |a ANDROMEDA Trial Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Augustson, Bradley |e investigator |4 oth | |
| 700 | 1 | |a Kwok, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Mollee, Peter |e investigator |4 oth | |
| 700 | 1 | |a Gibbs, Simon |e investigator |4 oth | |
| 700 | 1 | |a Doyen, Chantal |e investigator |4 oth | |
| 700 | 1 | |a Bries, Greet |e investigator |4 oth | |
| 700 | 1 | |a Vande Broek, Isabelle |e investigator |4 oth | |
| 700 | 1 | |a Wu, Ka Lung |e investigator |4 oth | |
| 700 | 1 | |a Theunissen, Koen |e investigator |4 oth | |
| 700 | 1 | |a Van Eygen, Koen |e investigator |4 oth | |
| 700 | 1 | |a Delforge, Michel |e investigator |4 oth | |
| 700 | 1 | |a Meuleman, Nathalie |e investigator |4 oth | |
| 700 | 1 | |a Vlummens, Philip |e investigator |4 oth | |
| 700 | 1 | |a Maiolino, Angelo |e investigator |4 oth | |
| 700 | 1 | |a de Gusmão, Breno Moreno |e investigator |4 oth | |
| 700 | 1 | |a Miguel, Carlos Eduardo |e investigator |4 oth | |
| 700 | 1 | |a Crusoe, Edvan |e investigator |4 oth | |
| 700 | 1 | |a Moura, Fernanda |e investigator |4 oth | |
| 700 | 1 | |a Seguro, Fernanda |e investigator |4 oth | |
| 700 | 1 | |a Bigonha, Jandey |e investigator |4 oth | |
| 700 | 1 | |a Musacchio, Juliane |e investigator |4 oth | |
| 700 | 1 | |a Zanella, Karla |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Laura |e investigator |4 oth | |
| 700 | 1 | |a Zanella Capra, Marcelo Eduardo |e investigator |4 oth | |
| 700 | 1 | |a de Assis, Reijane Alves |e investigator |4 oth | |
| 700 | 1 | |a Bittencourt, Rosane |e investigator |4 oth | |
| 700 | 1 | |a Hungria, Vania |e investigator |4 oth | |
| 700 | 1 | |a Braga, Walter |e investigator |4 oth | |
| 700 | 1 | |a Barreto, Wolney |e investigator |4 oth | |
| 700 | 1 | |a Venner, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Reece, Donna |e investigator |4 oth | |
| 700 | 1 | |a Lemieux-Blanchard, Emilie |e investigator |4 oth | |
| 700 | 1 | |a Song, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Sebag, Michael |e investigator |4 oth | |
| 700 | 1 | |a Lam, Selay |e investigator |4 oth | |
| 700 | 1 | |a Zepeda, Victor |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Haitao |e investigator |4 oth | |
| 700 | 1 | |a Hu, Jianda |e investigator |4 oth | |
| 700 | 1 | |a Lu, Jin |e investigator |4 oth | |
| 700 | 1 | |a Li, Juan |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Songfu |e investigator |4 oth | |
| 700 | 1 | |a Niu, Ting |e investigator |4 oth | |
| 700 | 1 | |a Chen, Wenming |e investigator |4 oth | |
| 700 | 1 | |a Chen, Xiaonong |e investigator |4 oth | |
| 700 | 1 | |a Cai, Zhen |e investigator |4 oth | |
| 700 | 1 | |a Fude, Zhou |e investigator |4 oth | |
| 700 | 1 | |a Vase, Maja Oelholm |e investigator |4 oth | |
| 700 | 1 | |a Salomo, Morten |e investigator |4 oth | |
| 700 | 1 | |a Abildgaard, Niels |e investigator |4 oth | |
| 700 | 1 | |a Fuzibet, Alain |e investigator |4 oth | |
| 700 | 1 | |a Stoppa, Anne-Marie |e investigator |4 oth | |
| 700 | 1 | |a Jaccard, Arnaud |e investigator |4 oth | |
| 700 | 1 | |a Arnulf, Bertrand |e investigator |4 oth | |
| 700 | 1 | |a Moulin, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Royer, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Ghez, David |e investigator |4 oth | |
| 700 | 1 | |a Caillot, Denis |e investigator |4 oth | |
| 700 | 1 | |a Chauveau, Dominique |e investigator |4 oth | |
| 700 | 1 | |a Bridoux, Franck |e investigator |4 oth | |
| 700 | 1 | |a Clement-Filliatre, Lauriane |e investigator |4 oth | |
| 700 | 1 | |a Karlin, Lionel |e investigator |4 oth | |
| 700 | 1 | |a Benboubker, Lotfi |e investigator |4 oth | |
| 700 | 1 | |a Dib, Mamoun |e investigator |4 oth | |
| 700 | 1 | |a Macro, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Mohty, Mohamad |e investigator |4 oth | |
| 700 | 1 | |a Decaux, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Hermine, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Tournilhac, Olivier |e investigator |4 oth | |
| 700 | 1 | |a Moreau, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Manier, Salomon |e investigator |4 oth | |
| 700 | 1 | |a Choquet, Sylvain |e investigator |4 oth | |
| 700 | 1 | |a Dorvaux, Véronique |e investigator |4 oth | |
| 700 | 1 | |a Carpinteiro, Alexander |e investigator |4 oth | |
| 700 | 1 | |a Nogai, Axel |e investigator |4 oth | |
| 700 | 1 | |a Besemer, Britta |e investigator |4 oth | |
| 700 | 1 | |a Roellig, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Fenk, Roland |e investigator |4 oth | |
| 700 | 1 | |a Knop, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Schönland, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Hansen, Timon |e investigator |4 oth | |
| 700 | 1 | |a Symeonidis, Argiris |e investigator |4 oth | |
| 700 | 1 | |a Kastritis, Efstathios |e investigator |4 oth | |
| 700 | 1 | |a Mikala, Gabor |e investigator |4 oth | |
| 700 | 1 | |a Masszi, Tamás |e investigator |4 oth | |
| 700 | 1 | |a Nagy, Zsolt |e investigator |4 oth | |
| 700 | 1 | |a Suriu, Celia |e investigator |4 oth | |
| 700 | 1 | |a Magen, Hila |e investigator |4 oth | |
| 700 | 1 | |a Vaxman, Iuliana |e investigator |4 oth | |
| 700 | 1 | |a Shvidel, Lev |e investigator |4 oth | |
| 700 | 1 | |a Preis, Meir |e investigator |4 oth | |
| 700 | 1 | |a Gatt, Moshe |e investigator |4 oth | |
| 700 | 1 | |a Lavi, Noa |e investigator |4 oth | |
| 700 | 1 | |a Jarchowsky, Osnat |e investigator |4 oth | |
| 700 | 1 | |a Tadmor, Tamar |e investigator |4 oth | |
| 700 | 1 | |a Cohen, Yael |e investigator |4 oth | |
| 700 | 1 | |a Vacca, Angelo |e investigator |4 oth | |
| 700 | 1 | |a Palladini, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a Boccadoro, Mario |e investigator |4 oth | |
| 700 | 1 | |a Martelli, Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Musso, Maurizio |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 385(2021), 1 vom: 01. Juli, Seite 46-58 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2021 |g number:1 |g day:01 |g month:07 |g pages:46-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2028631 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2021 |e 1 |b 01 |c 07 |h 46-58 | ||